Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that William Rote, Ph.D., the Company’s chief research officer, plans to retire from the Company in February 2027 following 10 years of ...
Detailed price information for Travere Therapeutics Inc (TVTX-Q) from The Globe and Mail including charting and trades.
Travere Therapeutics said Chief Research Officer William Rote plans to retire from the company in February. Chief Medical Officer Julia Inrig will expand her responsibilities to include the company's ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Mornings like we had on Wednesday are exactly why I get up and ...
AZN's Ultomiris wins FDA priority review for IgAN, backed by late-stage data showing a 43.4% proteinuria reduction versus ...
Piper Sandler analyst Allison Bratzel maintained a Buy rating on Abivax SA Sponsored ADR today and set a price target of $165.00. Claim 55% Off TipRanks. Unlock powerful investing ...
June 22 () - Nuvectis Pharma said on Monday it had licensed exclusive rights outside China to two experimental drugs from Haisco Pharmaceutical Group, targeting complement-mediated diseases and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results